## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.29 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($448.62)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. HCA Healthcare UK Goes On “The Cloud” with MEDITECH Expanse EHR, Powering Patient-Centred Care**
- Source: PA Media | 20251218T083709 | Bullish | Relevance: 100%
- HCA Healthcare UK has implemented MEDITECH Expanse EHR in the cloud to enhance patient-centric care. This move signifies a major step in digital transformation, aiming to improve healthcare delivery across their facilities. The project involves executives celebrating the live launch of this advanced electronic health record system.

**2. HCA Healthcare UK Goes On “The Cloud” with MEDITECH Expanse EHR, Powering Patient-Centred Care**
- Source: Business Wire | 20251218T080823 | Bullish | Relevance: 100%
- HCA Healthcare UK has successfully implemented MEDITECH Expanse, a cloud-based Electronic Health Record (EHR) system, across its 11 acute facilities and numerous outpatient locations. This deployment aims to standardize care, enhance patient safety through electronic medication management, and improve workflow efficiencies by providing clinicians with a unified view of patient journeys. The system, hosted on the Google Cloud Platform, also supports future technologies like AI and facilitates secure, remote access to patient information.

**3. HCA Healthcare (NYSE:HCA) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says**
- Source: MarketBeat | 20251219T145125 | Bullish | Relevance: 100%
- Royal Bank of Canada upgraded its price target for HCA Healthcare (NYSE:HCA) to $525 from $482, maintaining an "outperform" rating and implying a 12.63% upside. This follows HCA's stronger-than-expected quarterly earnings of $6.96 EPS and $19.16 billion revenue. The company also issued a favorable FY2025 EPS guidance, and institutional investors hold a significant stake in the company.

**4. HCA Healthcare stock rating reiterated at Overweight by Cantor Fitzgerald**
- Source: Investing.com | 20251219T134418 | Bullish | Relevance: 100%
- Cantor Fitzgerald has reiterated an Overweight rating on HCA Healthcare Inc (NYSE:HCA) with a price target of $525.00, citing a positive shift in investor sentiment regarding HCA’s 2026 EBITDA growth prospects and increasing confidence in its core strength. The firm also noted survey findings that suggest the impact of enhanced Affordable Premium Tax Credits (eAPTC) expiration might affect pricing more than volume, contrasting HCA's own commentary. HCA Healthcare operates extensively across the US and UK, and recent news highlights strong financial performance and strategic financial management.

**5. Texas Permanent School Fund Corp Has $4.66 Million Stock Holdings in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251218T110838 | Bullish | Relevance: 100%
- Texas Permanent School Fund Corp recently reduced its stake in HCA Healthcare by 37.3%, now holding shares valued at $4.66 million. Despite this, HCA Healthcare reported strong Q2 earnings, beating analyst expectations, and major institutional investors like Norges Bank and Viking Global Investors LP increased their positions. Analysts maintain a "Moderate Buy" rating for HCA with a consensus target price of $475.95.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $520 | $505 | +3% |
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Outperform |
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.29 suggests fair value with growth premium. Forward P/E 15.9x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.7B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.29 |
| Forward P/E | 15.9 |
| Current P/E | 17.1 |
| YoY Growth | 7.6% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -2.2% to -3.3% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.3pp (needs >4.0% for momentum thesis). AM_20 at -3.0% indicates price below own 20MA trend. Underperforming sector by 3.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-3.89), momentum weakening. RSI neutral at 47. Elevated volume (1.6x 20MA), institutional activity likely. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.34% (CS: 18) | Weak |
| RSI_14 | 46.9 | Neutral |
| MACD Histogram | -3.89 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 1.010x | Above |
| vs SMA200 | 1.194x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $472.86
- **Stop Loss:** $448.62 (5.1% risk)
- **Target:** $521.34 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $23,170.14
- **Portfolio %:** 23.17%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*